LAVAL, Quebec-(BUSINESS WIRE)- Altasciences, een middelgrote CRO die gespecialiseerd is in een flexibele, innovatieve aanpak voor het leveren van een uitgebreide vroegtijdige ontwikkeling van geneesmiddelenontwikkeling, van de selectie van de belangrijkste kandidaten tot het bewijs van het concept, kondigde vandaag aan dat ze een overeenkomst hebben gesloten om WuXi AppTec’s Investigational New Drug (WIND)-platform te ondersteunen. WIND combineert CRO-diensten van wereldklasse met cross-functioneel programmabeheer en wereldwijde expertise op het gebied van regelgeving om IND-toepassingen te ondersteunen. WuXi Clinical, de klinische CRO tak van WuXi AppTec, zal verantwoordelijk zijn voor het beheer van de samenwerking en het verzekeren van een naadloze ervaring.
Altasciences zal zijn full-service oplossingen bieden, waaronder klinische farmacologie, first-in-humane en proof-of-concept trials, programmamanagement, medical writing, biostatistiek en datamanagement ter ondersteuning en uitvoering van uitgebreide vroegtijdige klinische diensten voor WuXi AppTec’s meervoudige lopende WIND programma’s.
Altasciences and WuXi AppTec Enter Into Collaboration for WIND Projects
LAVAL, Quebec–(BUSINESS WIRE)– Altasciences, a mid-size CRO specializing in a flexible, innovative approach to providing comprehensive early stage drug development from lead candidate selection to proof of concept, announced today that they have entered into an agreement to support WuXi AppTec’s Investigational New Drug (WIND) platform. WIND combines world-class CRO services with cross-functional program management and global regulatory expertise to support IND applications. WuXi Clinical, the clinical CRO arm of WuXi AppTec, will be responsible for managing the partnership and ensuring a seamless experience.
Altasciences will provide its full-service solutions, including clinical pharmacology, first-in-human and proof-of-concept trials, program management, medical writing, biostatistics, and data management to support and conduct comprehensive early phase clinical services for WuXi AppTec’s multiple ongoing WIND programs.
“WuXi AppTec and Altasciences share the same vision, which is to provide a seamless, integrated transition from one key milestone to the next during the early phases of drug development. I am confident that together, we will continue on our path to help sponsors research and develop potentially life-saving therapeutics, faster,” stated Chris Perkin, CEO, Altasciences.
With integrated capabilities in toxicology, DMPK, pharmacology, CMC, and analytical services, WuXi AppTec supports the full scope of drug development programs, from IND-enabling studies to regulatory support for both pre-IND and post-IND stages, as well as document preparation and submission.
“Altasciences has strong expertise and deep experience in early phase clinical research. The partnership is an excellent complement for WuXi to help our global collaborators to expedite the R&D process from pre-IND to clinical stages and bring better therapies to patients far faster,” said Edward Hu, Co-CEO, WuXi AppTec.
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies of all sizes a proven, flexible approach to preclinical and early phase clinical studies, from lead candidate selection to proof of concept. For over 25 years, Altasciences has been integrating into clients’ projects to help support educated, faster, and more complete early drug development decisions. Altasciences’ full-service solutions include preclinical safety testing, clinical pharmacology, bioanalysis, program management, medical writing, biostatistics, and data management, all of which can be tailored to specific sponsor requirements. Altasciences… helping sponsors get better drugs to the people who need them, faster.
About WuXi AppTec
WuXi AppTec is a leading pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our customers and partners worldwide shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, the WuXi platform is enabling more than 3,500 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi’s dream that “every drug can be made and every disease can be treated.”